Compare INKT & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INKT | ENLV |
|---|---|---|
| Founded | 2017 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.7M | 4.0M |
| IPO Year | 2021 | 2014 |
| Metric | INKT | ENLV |
|---|---|---|
| Price | $8.60 | $1.11 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $44.00 | N/A |
| AVG Volume (30 Days) | 11.9K | ★ 95.1K |
| Earning Date | 11-11-2026 | 12-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.48 | $0.16 |
| 52 Week High | $15.27 | $7.64 |
| Indicator | INKT | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 30.86 | 49.47 |
| Support Level | N/A | $1.02 |
| Resistance Level | $11.92 | $1.26 |
| Average True Range (ATR) | 0.69 | 0.12 |
| MACD | -0.15 | -0.05 |
| Stochastic Oscillator | 9.38 | 20.54 |
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.